共 229 条
[1]
Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[2]
Therasse P(2014)The components of progression as explanatory variables for overall survival in the response evaluation criteria in solid tumours 1.1 database Eur J Cancer 50 1847-1853
[3]
Bogaerts J(2015)“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy Breast Cancer Res 17 150-160
[4]
Schwartz LH(2011)Immune parameters affecting the efficacy of chemotherapeutic regimens Nat Rev Clin Oncol 8 151-306
[5]
Sargent D(2012)The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 298-1433
[6]
Ford R(2013)Breakthrough of the year 2013. Cancer immunotherapy Science 342 1432-674
[7]
Dancey J(2011)Hallmarks of cancer: the next generation Cell 144 646-160
[8]
Arbuck S(2014)Crosstalk between CTC, immune system and hypoxic tumor microenvironment Cancer Microenviron 7 153-1505
[9]
Gwyther S(2014)Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states Br J Cancer 110 1497-1342
[10]
Mooney M(2014)Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models Cancer Sci 105 1334-923